Skip to main content Accessibility help
×
Home
  • Get access
    Check if you have access via personal or institutional login
  • Cited by 1
  • Print publication year: 2008
  • Online publication date: August 2009

1 - Introduction

Summary

Cancer patients experience a number of adverse symptoms, including cognitive impairment, fatigue, pain, sleep disturbance, and others often in combination rather than alone. Fortunately detailed symptom assessment is becoming increasingly recognized as a part of routine patient care by physicians, allied health care providers, and accrediting agencies. Cancer treatment may only be considered successful if these symptoms are managed, but successful management is hampered by insufficient knowledge of mechanisms.

Cognitive dysfunction occurs in the majority of cancer patients on active therapy, and is not infrequently a symptom that heralds the diagnosis. In addition, it persists in a substantial number of patients long after treatment is discontinued. In some situations this type of cognitive dysfunction is popularly termed “chemobrain” or “chemofog” although cognitive impairment can be due to a large number of factors (Table 1.1), many of which are discussed in detail throughout this text.

The components of cognitive dysfunction will vary as a result of the specific etiology, but there are several core cognitive domains that appear to be differentially affected. Cancer patients with cognitive dysfunction often present with complaints of memory disturbance. However, objective testing of memory generally demonstrates a restriction of working memory capacity (e.g., the person is able to learn less information, and learning may be less efficient), and inefficient memory retrieval (e.g., spontaneous recall may be somewhat spotty).

REFERENCES
Dropcho, EJ (2005). Update on paraneoplastic syndromes. Curr Opin Neurol 18(3): 331–336.
Lee, BN, Dantzer, R, Langley, KEet al. (2004). A cytokine-based neuroimmunological mechanism of cancer-related symptoms. Neuroimmunomodulation 11: 279–292.
Meyers, CA, Kudelka, AP, Conrad, CA, Gelke, CK, Grove, W, Pazdur, R (1997). Neurotoxicity of CI-980, a novel mitotic inhibitor. Clin Cancer Res 3: 419–422.
Meyers, CA, Albitar, M, Estey, E (2005). Cognitive impairment, fatigue, and cytokine levels in patients with acute myelogenous leukemia or myelodysplastic syndrome. Cancer 104: 788–793.
Scheibel, RS, Valentine, AD, O'Brien, S, Meyers, CA (2004). Cognitive dysfunction and depression during treatment with interferon-alpha and chemotherapy. J Neuropsychiatry Clin Neurosci 16: 185–191.
Wefel, JS, Lenzi, R, Theriault, RL, Davis, RN, Meyers, CA (2004). The cognitive sequelae of standard dose adjuvant chemotherapy in women with breast cancer: results of a prospective, randomized, longitudinal trial. Cancer 100: 2292–2299.